Skip to main content
Premium Trial:

Request an Annual Quote

Abbott Labs and Celera Genomics Link on Cancer Therapeutics Development

NEW YORK, July 7 (GenomeWeb News) - Abbott Laboratories and Celera Genomics Group today announced a partnership to develop therapeutic antibodies and small-molecule drugs against over-expressed cell-surface proteins associated with cancer.


Celera will contribute a subset of the cell-surface antigens it has identified and validated in its ongoing proteomic studies in a number of solid tumors, the company said. Abbott will screen the antigens to identify those with potential for subsequent preclinical development.


In the collaboration, the two companies may elect to jointly fund clinical development and commercialization of any therapeutic products and share the financial returns resulting from this, he companies said. Abbott will be responsible for commercialization of jointly-funded collaboration products.


If either company opts to not jointly clinical development of a resulting product, the terms of the agreement will revert to a milestone and royalty structure. Additionally, Celera will receive milestone payments on reaching certain preclinical milestones. Celera retains certain diagnostic rights associated with selected targets.

The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.